跳至主要内容
临床试验/NCT04789993
NCT04789993Unknown不适用

Additional Autoimmune Diseases With Type 1 Diabetes in Children and Adolescents at Diabetes Diagnostic and During Follow-up : a Monocentric Study in France

Central Hospital, Nancy, France1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2021年3月15日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
250
试验地点
1
主要终点
Type of additional autoimmune diseases at type 1 diabetes diagnosis

研究概览

简要总结

This study aims to describe the prevalence of additional autoimmune diseases and their specific antibodies at type 1 diabetes (T1D) diagnosis, and their incidence rate during follow-up, for children and adolescents. It also aims to describe the characteristics of the pediatric cohort followed since 2014 for type 1 diabetes by one of France's centers of reference for paediatric diabetes.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
6 Months 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with type 1 diabetes diagnosed with the following criteria: (i) Classic symptoms of diabetes or hyperglycemic crisis, with plasma glucose concentration ≥11.1 mmol/L (200 mg/dl), or (ii) fasting plasma glucose ≥7.0 mmol/l (≥126 mg/dl) ; and (iii) presence of diabetes associated autoantibodies : ICA, GAD, IA2, IAA and/or ZnT8
  • age < 18 years old at type 1 diabetes diagnostic
  • type 1 diabetes diagnosed between 2014-01-01 and 2021-02-01

排除标准

  • type 1 diabetes diagnostic not certain

结局指标

主要结局

Type of additional autoimmune diseases at type 1 diabetes diagnosis

时间窗: up to 3 weeks after type 1 diabetes diagnosis

Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations

Number of additional autoimmune diseases at type 1 diabetes diagnosis

时间窗: up to 3 weeks after type 1 diabetes diagnosis

Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations

次要结局

  • Occurence or non-occurence of antibodies specific to each additional autoimmune disease listed in outcome 5(From type 1 diabetes diagnosis to last news date, from 1 to 6 years)
  • Description of the autoimmune characteristics of all the patients followed in our cohort of pediatric type 1 diabetes(during follow-up : From type 1 diabetes diagnosis to last news date, from 1 to 6 years)
  • Occurence of specific treatment onset in patients followed for type 1 diabetes with thyroid dysfunction due to Hashimoto(From type 1 diabetes diagnosis to last news date, from 1 to 6 years)
  • Characteristics of patients, for each type of antibodies specific to an autoimmune disease, present or absent at type 1 diabetes diagnostic(up to 3 weeks after type 1 diabetes diagnosis)
  • Occurence or non-occurence of at least one type of antibody specific to an additional autoimmune disease(From type 1 diabetes diagnosis to last news date, from 1 to 6 years)
  • If patient diagnosed with Hashimoto when type 1 diabetes is diagnosed, proportion of patients with thyroid dysfunction(Up to 3 weeks after type 1 diabetes diagnosis)
  • Characteristics of patients, if additional autoimmune disease is present or absent(up to 3 weeks after type 1 diabetes diagnosis)
  • Occurence or non-occurence of at least one additional autoimmune diseases during follow-up(From type 1 diabetes diagnostic to last news date, an average of 3 years)
  • Occurence or non-occurence of each type of additional autoimmune disease during follow-up(From type 1 diabetes diagnostic to last news date, an average of 3 years)
  • Description of the characteristics of all the patients followed in our cohort of pediatric type 1 diabetes(Up to 3 weeks after type 1 diabetes diagnosis)
  • Presence of antibodies specific to an additional autoimmune disease at type 1 diabetes diagnostic(up to 3 weeks after type 1 diabetes diagnosis)
  • Occurence of thyroid dysfunction in patients with type 1 diabetes and Hashimoto(From type 1 diabetes diagnosis to last news date, from 1 to 6 years)
  • Characteristics of patients, if at least one type of antibodies specific to an autoimmune disease is present or absent at type 1 diabetes diagnostic(up to 3 weeks after type 1 diabetes diagnosis)
  • If detection of antibodies specific to an additional autoimmune disease : delay between detection of these antibodies and diagnosis of the corresponding autoimmune disease(From type 1 diabetes diagnosis to last news date, from 1 to 6 years)
  • Proportion of patients with thyroid dysfunction due to Hashimoto needing a specific treatment(Up to 3 weeks after type 1 diabetes diagnosis)

研究者

发起方
Central Hospital, Nancy, France
申办方类型
Other
责任方
Principal Investigator
主要研究者

LEGAGNEUR Carole

MD

Central Hospital, Nancy, France

研究点 (1)

Loading locations...

相似试验

Additional Autoimmune Diseases With Type 1 Diabetes... | 临床试验